June, 2024
June 2024
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
First prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced NSCLC – Top Science
May 19, 2024, 05:07

First prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced NSCLC – Top Science

Top Science shared on X:

This is the first prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced Non- Small Cell Lung Cancer (NSCLC).

Sintilimab was efficacious and well-tolerated irrespective of PD-L1 expression level in patients with advanced NSCLC and had similar efficacy and safety to Pembrolizumab.

Additional information.
Source: Top Science/X